DarioHealth

Aging Demographics And Telehealth Will Transform Chronic Care

AnalystHighTarget

Not Invested

Consensus Narrative from 4 Analysts

Published

17 Aug 25

Updated

17 Aug 25

AnalystHighTarget's Fair Value

US$4.00

89.0% undervalued

17 Aug

US$0.44

-52.2%

2.7%

Author's Valuation

US$4.0

89.0% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$4.0

89.0% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

18.46%

Healthtech revenue growth rate

4.71%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

11.71%

Calculation

US$7.76m

Earnings '28

71.83x

PE Ratio '28

US$557.42m

Market Cap '28

US$557.42m

Market Cap '28

99.96m

No. shares '28

US$5.58

Share Price '28

US$5.58 Share Price '28

Discounted to 2025 @ 11.71% p.a.

US$4.00

Fair Value '25